^
    Back
    Association details:
    Biomarker:MLL fusion
    Cancer:Acute Myelogenous Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    azacitidine (DNMT inhibitor) +
    Farydak (panobinostat) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2018
    Title:

    Epigenetic Drug Combination Chemo-Sensitizes Pediatric AML By Reducing Cell Adhesion and Dislodging AML Cells from the Bone Marrow

    Published date:
    11/01/2018
    Excerpt:
    AML cell lines and PDX lines were co-cultured with HS5 bone marrow stromal cells….Pre-treatment with the epigenetic drug combination of azacitidine and panobinostat prior to cytarabine exposure greatly reduced cell viability in MV4;11 cells harboring KMT2A fusion (Fig. 1A).
    DOI:
    10.1182/blood-2018-99-120321